At present, Addyi is only FDA approved for use in premenopausal women with hypoactive sexual desire disorder (HSDD).
There has been a study called the SNOWDROP trial which assessed the effectiveness of flibanserin (Addyi) in over 900 postmenopausal women with HSDD. The results were positive, with flibanserin (Addyi) demonstrating a significant improvement in sexual desire compared to a placebo.
Doctors may still prescribe a drug for an indication for which it is not approved. This is known as "off-label" drug use. If you are postmenopausal and suffer from hypoactive sexual desire disorder, talk to your doctor about your options.
- Addyi Information for Consumers
- Addyi Information for Healthcare Professionals (includes dosage details)
- Side Effects of Addyi (detailed)
Search for questions
Still looking for answers? Try searching for what you seek or ask your own question.
Updated 1 Mar 2012 • 3 answers
Updated 8 Sep 2015 • 1 answerFAQ by Drugs.com
Updated 16 Dec 2017 • 4 answers
Updated 30 Jul 2018 • 2 answers
Posted 12 Sep 2018 • 0 answers